Company: PCRX
Filing Date: 2025-07-07
Form Type: 8-K
Source: 0001104659-25-065979
Chunk: 2

Company: Pacira BioSciences, Inc.
Filing Date: 2025-07-07
Form: 8-K
Item: Item 1.02
Chunk 2
---
Item 1.02. Termination of a Material Definitive Agreement.

On July 3, 2025, the Company used a portion of
the $300.0 million of revolving loans to repay the indebtedness outstanding under the Existing Credit Agreement and terminated the Existing
Credit Agreement. The Company did not incur any prepayment penalties or fees in connection with the termination of the Existing Credit
Agreement. A description of the Existing Credit Agreement is included in the Company’s Current Reports on Form 8-K, filed with the
Securities and Exchange Commission on April 3, 2023 and May 8, 2024, each of which is incorporated herein by reference.

The information set forth in Item 1.01 of this
Current Report on Form 8-K is incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this
Current Report on Form 8-K is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.